Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Public comment period · §2

Draft methodological review: transitivity in the incretin… — submissions

The 9 submissions received, published in full with declared interests and secretariat responses.

Document identifier
CEI-CP-009/2
Series
Public comment period
Version
1.0
Published
20 Mar 2026
Last reviewed
20 Mar 2026
Next review
20 Mar 2027
Identifier
10.71829/cei.cp.9
Certainty
Not rated
Cycle
2026 Q1
Window
06 Jan 2026 – 03 Mar 2026
Status
Closed
Submissions
9

§2Submissions and responses

9 submissions were received. Each is published in full below with its declared interest, the secretariat response and the disposition. The Institute publishes submissions it did not accept in the same form as those it did.

Dr Eamon Immelmann, MD, DPhil Metabolic medicine service, tertiary centre
DRAFT-NETWORK-TRAN/001 received 18 Jan 2026

Studies using different outcome definitions are pooled into one estimate

The contributing studies define the outcome in at least two ways, and the draft pools them. The respondent states that the resulting estimate is an average across definitions rather than an estimate of any one quantity.

The respondent proposes that studies be pooled only within a definition, and that the definitions be reported separately with their own certainty ratings.

Declared interest. Is a member of the Institute's external reviewer register but did not review the document under consultation.
Secretariat responseAccepted01 Apr 2026

The secretariat accepts this submission. Pooling across definitions produces a figure with no referent, and the draft did it without saying so.

Studies are now pooled only within an outcome definition, each definition is reported with its own estimate and certainty rating, and the summary of findings states which definition each row concerns.

Dr Quintus Rautavaara, PhD (Pharmacology) Hospital microbiology and endotoxin testing service
DRAFT-NETWORK-TRAN/005 received 24 Jan 2026

Declared interests should appear on the document rather than on a separate page

The draft links to a central conflicts register. The respondent argues that a reader assessing whether to rely on a particular document should not have to leave it to find out who assessed it and what they declared.

The respondent proposes that the interests of every named contributor to a document be printed on that document.

Declared interest. Is a practising clinician who prescribes compounds in the class under assessment. No financial relationship with any manufacturer.
Secretariat responseNoted, no amendment09 Mar 2026

The secretariat notes this submission and records that the draft already provides for it, which the respondent could reasonably have missed because the provision sits in an appendix.

Every document carries the declared interests of its named contributors in its front matter, and the central register exists so that a reader can see a person across all documents rather than one at a time. No amendment arises; the provision has been moved from the appendix into the body of the methodology document so that it is findable.

Dr Henrike Jastrzębska, MSc, CChem Academic sports-medicine and anti-doping laboratory
DRAFT-NETWORK-TRAN/004 received 28 Jan 2026

The document should state what a reader ought to do

The draft assesses evidence and stops. The respondent, a practising clinician, states that a reader arriving at the document with a decision to make is left to convert an assessment into an action without help, and proposes that each document close with a recommendation.

The respondent argues that other evidence bodies issue recommendations and that declining to do so transfers the difficult part of the work to the reader.

Declared interest. Has used a compound in the class under assessment under prescription. Declared at the Institute's request; the Institute regards a lived-experience declaration as an interest and not as a disqualification.
Secretariat responseNot accepted09 Mar 2026

The secretariat does not accept this submission, and records that the point is a reasonable one rather than a misunderstanding.

The Institute assesses evidence and does not issue recommendations, because a recommendation embeds values and a resource context that the Institute does not hold and cannot state. That constitutional limit is published on the methodology page and is not varied by consultation. The submission remains published in full.

Dr Wilhelmina Erlingsson, RN, MSc (Advanced Practice) Sleep and respiratory medicine service
DRAFT-NETWORK-TRAN/007 received 04 Feb 2026

The document is unreadable without specialist training

The respondent, a trustee of a patient organisation, states that the draft is written for a reader who already understands certainty grading, and that the people most affected by the subject matter will not reach the assessment at all.

The respondent proposes a plain-language summary at the head of every document, written to the same standard of accuracy as the document itself and not as a promotional abstract.

Declared interest. Holds a personal shareholding, below the Institute's materiality threshold, in a diversified fund with pharmaceutical sector exposure. No direct holding in any named company.
Secretariat responseAccepted in part31 Mar 2026

The secretariat accepts this submission in part. A plain-language summary is added. The proposal that it replace the technical abstract is declined, because the abstract is the part of the document other assessors read and cite.

Every document now opens with a plain-language summary of not more than 150 words, placed above the technical abstract and carrying the same certainty language, so that the two cannot diverge.

Dr Gervase Crickhowell, MD, MPH Primary-care research network
DRAFT-NETWORK-TRAN/006 received 13 Feb 2026

The review protocol is described but its registration record is not linked

The respondent asks for the prospective registration record of the review protocol so that the registered outcomes can be compared with the reported ones.

The respondent states that without it the claim of prospective registration cannot be checked.

Declared interest. Has previously served as an investigator on a trial included in the evidence base under consultation. Received no personal payment; institutional payment was made to the trial site.
Secretariat responseAccepted in part14 Mar 2026

The secretariat accepts this submission in part. The protocol is published in full on the Institute site with its version history, which permits the comparison the respondent asks for. Where an external registration identifier is not held by the Institute, the review says so rather than supplying one.

Each synthesis now links its own protocol with the version in force at screening, and states explicitly where an external registration identifier is not held, so that the absence is a recorded fact.

Dr Liesbeth Zaleski-Mbeki, MD, FRCPath Academic biostatistics group
DRAFT-NETWORK-TRAN/002 received 23 Feb 2026

Absence of evidence is presented in a form a reader will take as negative evidence

Where the Institute has identified no study, the draft states that no evidence was found. In several places that sentence sits immediately after a paragraph describing an adverse outcome, and the juxtaposition invites the reading that the compound was studied and found wanting.

The respondent proposes a standing formulation, used identically wherever the situation arises, distinguishing an outcome that was studied and not demonstrated from an outcome that has not been studied at all.

Declared interest. Has received consultancy fees from a supplier named in the Institute's supplier assessment set within the preceding two years.
Secretariat responseAccepted01 Apr 2026

The secretariat accepts this submission. The two states are different, they support different decisions, and the draft rendered them in language a reader could not reliably separate.

A standing formulation has been adopted and is applied wherever an evidence gap is recorded, distinguishing an outcome assessed and not demonstrated from an outcome not assessed. The formulation is identical at every occurrence so that it can be recognised at a glance.

Dr Adaeze Dunmore-Ekpo, MD, MSc Community pharmacy practice, doctoral candidate
DRAFT-NETWORK-TRAN/008 received 26 Feb 2026

Point estimates are given without an interval

Several estimates in the draft appear as single figures. The respondent states that a point estimate without an interval invites a precision the underlying data do not support, and that the effect is worst where the estimate is drawn from a small contributing set.

The respondent proposes that no point estimate appear anywhere in the document set without its interval, including in summary tables and in the abstract.

Declared interest. Employed by an analytical laboratory that performs contract testing for suppliers, including at least one supplier named in the Institute's assessment set.
Secretariat responseAccepted in part19 Mar 2026

The secretariat accepts this submission in part. Intervals are added wherever the source reports one. The proposal is declined for figures the source published without an interval, because the Institute will not compute an interval a source did not report.

Every estimate now carries its interval where the source reported one, and where it did not, the estimate is annotated as reported without an interval rather than left to appear as a precise figure.

Dr Liesbeth Delacroix-Njoku, MD, PhD, FESC ISO/IEC 17025-accredited contract testing laboratory
DRAFT-NETWORK-TRAN/003 received 03 Mar 2026

The review does not say when it will be updated or what would trigger an update

The respondent states that a synthesis in a field where trials report frequently is out of date from the day it is published, and that a reader has no way to know whether the version in front of them is current.

The respondent proposes a stated trigger for an update as well as a scheduled review date.

Declared interest. Is an employee of a marketing-authorisation holder for a compound named in the draft. This submission is made on behalf of that company and is identified as an industry submission throughout.
Secretariat responseAccepted31 Mar 2026

The secretariat accepts this submission. A review date alone tells a reader when the document will be looked at, not whether it should already have been.

Every synthesis now records a scheduled review date and a stated update trigger, being the reporting of a trial that would materially change the contributing evidence, and the registered trials capable of triggering an update are listed by name.

Dr Hamish Nyquist-Obiora, MD, FRCPath Academic biostatistics group
DRAFT-NETWORK-TRAN/009 received 03 Mar 2026

Results at materially different follow-up durations are pooled

Contributing trials report the outcome at durations ranging across more than a year. The draft pools them into a single estimate. The respondent states that a mean at one duration and a mean at another are not estimates of the same quantity when the effect is still changing.

The respondent proposes that estimates be reported by duration band.

Declared interest. Employed by a university department that has received unrestricted research funding from a manufacturer of a compound in the class under assessment. The respondent had no role in that funding.
Secretariat responseAccepted26 Mar 2026

The secretariat accepts this submission. Pooling across durations assumes a plateau the contributing trials do not demonstrate.

Estimates are now reported by duration band, with the number of contributing trials and participants in each band stated, and no estimate is pooled across bands.

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

  1. International Organization for Standardization. ISO/IEC 17025:2017 General Requirements for the Competence of Testing and Calibration Laboratories. ISO/IEC Standard 2017;3rd edition. identifier not held by the Institute

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.